Stratification of Anatomical Imaging Features Between High-Risk and Non-High-Risk Groups in Neuroblastoma

被引:0
作者
Wang, Haoru [1 ]
Chen, Xin [1 ]
He, Ling [1 ]
Cai, Jinhua [1 ]
机构
[1] Chongqing Med Univ, Natl Clin Res Ctr Child Hlth & Disorders, Dept Radiol,Childrens Hosp,Chongqing Key Lab Child, Minist Educ Key Lab Child Dev & Disorders, 136 Zhongshan Rd 2, Chongqing 400014, Peoples R China
关键词
children; computed tomography; image-defined risk factors; magnetic resonance imaging; neuroblastoma; CLASSIFICATION-SYSTEM; SINGLE;
D O I
10.1177/10732748251315883
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: This study compared anatomical imaging features between high-risk and non-high-risk groups in neuroblastoma with at least one image-defined risk factor (IDRF). It also assessed the diagnostic performance of these features in identifying the high-risk group. Methods: A retrospective analysis of neuroblastoma patients with at least one IDRF was conducted. Imaging features, including estimated tumor volume and IDRFs, were compared between the two groups. The diagnostic performance of these features was assessed using receiver operating characteristic (ROC) curves, and the areas under the ROC curves (AUCs) along with their 95% confidence intervals (CIs) were calculated. Additionally, to internally validate their diagnostic performance, the bootstrap resampling method with 1000 bootstrap resamples was employed. Results: The study included 255 patients (185 high-risk cases, 70 non-high-risk cases). Significant differences were found in estimated tumor volume and IDRF number between the high-risk and non-high-risk groups (P < 0.001). The estimated tumor volume and the IDRF number-based cluster were independent risk factors, and their combination achieved an AUC of 0.801 (95% CI: 0.747-0.848) for high-risk group diagnosis, with the average AUC of the 1000 bootstrap samples of 0.800 (95% CI: 0.798-0.802). In abdominal lesions, specific IDRF categories differed between high-risk and non-high-risk groups (P < 0.05). Conclusion: Our study reveals anatomical imaging differences between high-risk and non-high-risk groups in neuroblastoma with at least one IDRF.
引用
收藏
页数:12
相关论文
共 50 条
  • [11] Postchemotherapy gross residual tumor in non-high-risk neuroblastoma: Clinical significance and the role of adjuvant therapy
    Seo, Eun Seop
    Lim, Hana
    Cho, Hee Won
    Ju, Hee Young
    Lee, Ji Won
    Yoo, Keon Hee
    Lee, Sanghoon
    Lim, Do Hoon
    Sung, Ki Woong
    Koo, Hong Hoe
    PEDIATRIC BLOOD & CANCER, 2022, 69 (11)
  • [12] Improved risk stratification by PET-based intratumor heterogeneity in children with high-risk neuroblastoma
    Li, Chao
    Wang, Shaoyan
    Li, Can
    Yin, Yafu
    Feng, Fang
    Fu, Hongliang
    Wang, Hui
    Chen, Suyun
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [13] Histological features of primary tumors after induction or high-dose chemotherapy in high-risk neuroblastoma
    Hishiki, Tomoro
    Horie, Hiroshi
    Higashimoto, Yasuyuki
    Yotsumoto, Katsumi
    Komatsu, Shugo
    Okimoto, Yuri
    Kakuda, Harumi
    Taneyama, Yuichi
    Saito, Takeshi
    Terui, Keita
    Mitsunaga, Tetsuya
    Nakata, Mitsuyuki
    Ochiai, Hidemasa
    Hino, Moeko
    Ando, Kumiko
    Yoshida, Hideo
    Iwai, Jun
    PEDIATRIC SURGERY INTERNATIONAL, 2014, 30 (09) : 919 - 926
  • [14] Dinutuximab: A Review in High-Risk Neuroblastoma
    Sheridan M. Hoy
    Targeted Oncology, 2016, 11 : 247 - 253
  • [15] Retinoid therapy of high-risk neuroblastoma
    Reynolds, CP
    Matthay, KK
    Villablanca, JG
    Maurer, BJ
    CANCER LETTERS, 2003, 197 (1-2) : 185 - 192
  • [16] Evolving treatments in high-risk neuroblastoma
    Kumar, Abhinav
    Rocke, John P. J.
    Kumar, B. Nirmal
    EXPERT OPINION ON ORPHAN DRUGS, 2020, 8 (12): : 497 - 506
  • [17] Immunocombination therapy for high-risk neuroblastoma
    Kroesen, Michiel
    Lindau, Dennis
    Hoogerbrugge, Peter
    Adema, Gosse J.
    IMMUNOTHERAPY, 2012, 4 (02) : 163 - 174
  • [18] Mouse models of high-risk neuroblastoma
    Kamili, Alvin
    Atkinson, Caroline
    Trahair, Toby N.
    Fletcher, Jamie I.
    CANCER AND METASTASIS REVIEWS, 2020, 39 (01) : 261 - 274
  • [19] Dinutuximab: A Review in High-Risk Neuroblastoma
    Hoy, Sheridan M.
    TARGETED ONCOLOGY, 2016, 11 (02) : 247 - 253
  • [20] High-Risk Neuroblastoma Treatment Review
    Smith, Valeria
    Foster, Jennifer
    CHILDREN-BASEL, 2018, 5 (09):